12X1 Stock Overview A clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases in the United States. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Anavex Life Sciences Corp. Competitors Price History & Performance
Summary of share price highs, lows and changes for Anavex Life Sciences Historical stock prices Current Share Price US$8.30 52 Week High US$9.20 52 Week Low US$3.05 Beta 0.73 1 Month Change -2.35% 3 Month Change 68.39% 1 Year Change -2.99% 3 Year Change -45.75% 5 Year Change 226.77% Change since IPO -26.52%
Recent News & Updates
Anavex Life Sciences Corp. Receives EMA Filing Acceptance for Treatment of Alzheimer's Disease Dec 24
Anavex Life Sciences Corp. to Report Q4, 2024 Results on Dec 23, 2024 Dec 16
Anavex Life Sciences Announces Submission of Blarcamesine MAA for Treatment of Alzheimer’s Disease to EMA Nov 26
Anavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024 Oct 31
Anavex Life Sciences Corp Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia Oct 17 Anavex Life Sciences Corp. to Report Q3, 2024 Results on Aug 06, 2024 See more updates
Anavex Life Sciences Corp. Receives EMA Filing Acceptance for Treatment of Alzheimer's Disease Dec 24
Anavex Life Sciences Corp. to Report Q4, 2024 Results on Dec 23, 2024 Dec 16
Anavex Life Sciences Announces Submission of Blarcamesine MAA for Treatment of Alzheimer’s Disease to EMA Nov 26
Anavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024 Oct 31
Anavex Life Sciences Corp Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia Oct 17 Anavex Life Sciences Corp. to Report Q3, 2024 Results on Aug 06, 2024
Forecast breakeven date moved forward to 2025 Jul 30
Anavex Life Sciences Corp. Presents comprehensive results from the Phase IIb/III study of Blarcamesine at Alzheimer's Association Conference Jul 29
Insufficient new directors Jun 02
Anavex Life Sciences Corp Announces Management Appointments May 23
Anavex Life Sciences Corp., Annual General Meeting, Jun 18, 2024 May 08
Anavex Life Sciences Corp. to Report Q2, 2024 Results on May 09, 2024 May 03
Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®?3-71 in Schizophrenia Mar 19 Levi & Korsinsky, LLP Files Complaint Against Anavex Life Sciences Corporation Mar 14
Anavex Life Sciences Corp. to Report Q1, 2024 Results on Feb 07, 2024 Feb 02
Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of Anavex®3-71 in Schizophrenia Jan 17
Anavex Life Sciences Corp. Announces First Entire Clinical Gene Pathway Data of Anavex®2-73 from Avatar Study in Patients with Rett Syndrome Dec 21
Anavex Life Sciences Corp. Receives Agreement from the Committee for Medicinal Products for Human Use for the Submission of A Marketing Authorisation Application of Oral Blarcamesine for Alzheimer's Disease Dec 19
New major risk - Revenue and earnings growth Dec 17
Anavex Life Sciences Corp. to Report Fiscal Year 2023 Results on Nov 27, 2023 Nov 25
Anavex Initiates Regulatory Submission of Oral Blarcamesine for Alzheimer’s Disease to European Medicines Agency Nov 21
Anavex Life Sciences Corp. Appoints David Goldberger as Senior Vice President Regulatory Affairs Nov 07
Anavex Life Sciences Corp. Reports New Publication in Scientific Journal Demonstrating the Potential of ANAVEX(R) 3-71 to Prevent Cognitive Decline in Alzheimer's Disease Oct 26
Anavex Life Sciences Corp. Announces Phase 2b/3 Trial of Blarcamesine (ANAVEX 2-73) in Patients with Alzheimer’s Disease Shows Robust Clinical Efficacy and Slows Neurodegeneration Sep 15
Anavex Life Sciences Reports Publication of ANAVEX®?3-71 in Clinical Journal Confirming ANAVEX®? 3-71 Clinical Cardiovascular Safety Aug 08
Anavex Life Sciences Corp. to Report Q3, 2023 Results on Aug 08, 2023 Aug 03
Anavex Life Sciences Corp. Announces Long-Term Clinical Study Demonstrates Disease Modifying Effects of ANAVEX(R)2-73 (blarcamesine) for Rett Syndrome Jun 29
Anavex Life Sciences Corp.'s ANAVEX®2-73 (blarcamesine) Receives Compassionate Use Authorization for Pediatric Patients with Rett Syndrome Jun 16
Anavex Life Sciences Corp. Announces Completion of Anavex((R))2-73 (Blarcamesine) Excellence Phase 2/3 Rett Syndrome Clinical Trial Jun 07
Anavex Life Sciences Corp. Announces Exceeding of Enrollment Target for the ANAVEX(R)2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial Feb 03
Anavex Life Sciences Corp. to Report Q1, 2023 Results on Feb 07, 2023 Feb 01
Anavex Life Sciences Corp. Announces the Appointment of Timo Grimmer, Md, to Its Scientific Advisory Board Dec 15
ANAVEX®2–73 (Blarcamesine) Phase 2B/3 Study Met Primary and Key Secondary Endpoints, Showing Statistically Significant Reduction of Clinical Decline in Global Clinical Study of Patients With Early Alzheimer’s Disease Dec 02
Anavex Life Sciences Corp. to Report Q4, 2022 Results on Nov 28, 2022 Nov 24
Insufficient new directors Nov 16
Anavex Life Sciences Announces Late-Breaking Presentation of Phase 2B/3 Data of Oral Anavex®2-73 (Blarcamesine) for Early Alzheimer’s Disease At the Upcoming Clinical Trials on Alzheimer’S Disease (Ctad) Congress 2022 Oct 18
Forecast to breakeven in 2025 Oct 01 Anavex Life Sciences Corp. Reports New Publication in Medical Journal Highlighting the Relevance of Sigmar1 Activation to Compensate for Early Alzheimer's Disease Aug 24
Anavex Life Sciences Corp. to Report Q3, 2022 Results on Aug 09, 2022 Aug 04
Anavex Life Sciences Corp. to Report Q2, 2022 Results on May 10, 2022 May 04
Insufficient new directors Apr 27
Anavex Life Sciences Corp., Annual General Meeting, May 24, 2022 Apr 12
Anavex Life Sciences Provides Supplemental Information on ANAVEX®2-73 (Blarcamesine) AVATAR Phase 3 Trial for the Treatment of Adult Patients with Rett Syndrome Feb 05
Anavex Life Sciences Corp. to Report Q1, 2022 Results on Feb 09, 2022 Feb 04
Anavex Life Sciences Corp. Reports Positive Top-Line Results from the Phase 3 Randomized, Double-Blind, Placebo-Controlled AVATAR trial of ANAVEX®2-73 Feb 02
Anavex Life Sciences Corp. Reports Positive Results from Phase 1 Clinical Trial of ANAVEX3-71 Jan 12
Forecast to breakeven in 2024 Dec 08
No longer forecast to breakeven Nov 24
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Autism) Aug 27
Anavex Life Sciences Announces Anavex 2-73 (Blarcamesine) Biomarker Correlated with Efficacy Endpoints in Placebo-Controlled U.S. Phase 2 Clinical Trial for the Treatment of Adult Patients with Rett Syndrome Jun 22
Anavex Life Sciences Corp. Reports New Publication in Medical Journal Elucidating the Mechanism of Anavex®2-73 (Blarcamesine) and Anavex®3-71 (AF710B) Related to the Treatment of Alzheimer's Disease Jun 15
Anavex Life Sciences Announces Exceeding of Enrollment Target for the Precision Medicine ANAVEX®2-73 (Blarcamesine) Phase 2b/3 Clinical Trial in Patients with Alzheimer’s Disease Jun 09
Independent Director has left the company Jun 01
Forecast breakeven pushed back to 2024 May 17
Forecast breakeven pushed back to 2024 May 14
Anavex Life Sciences Reports Anavex®2-73 (Blarcamesine) Featured as Disease-Modifying Small Molecule in Phase 3 Clinical Trials Mar 17
Anavex Life Sciences Corp. to Report Q1, 2021 Results on Feb 11, 2021 Feb 10
New 90-day high: €5.50 Feb 03
Anavex Life Sciences Corp. to Report Fiscal Year 2020 Results on Dec 28, 2020 Dec 23
Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Meets Primary and Secondary Endpoints in Placebo-Controlled U.S. Phase 2 Clinical Trial for the Treatment of Adult Patients with Rett Syndrome Dec 17
Anavex Life Sciences Corp. Announces Notice of Allowance for U.S. Patent Application with Expanding Claims Covering ANAVEX®2-73 (blarcamesine) for the Treatment of Rett Syndrome and other Neurodevelopmental Disorders Dec 01
Anavex Life Sciences Corp. Announces Proof of Concept Controlled Phase 2 Clinical Trial Data Evaluating ANAVEX®2-73 (blarcamesine) in Parkinson’s Disease Dementia Presented at CTAD 2020 Conference Nov 07
New 90-day high: €5.05 Nov 01
Anavex Life Sciences Corp. Announces Positive Results from Proof of Concept controlled Phase 2 Clinical Trial Evaluating ANAVEX®2-73 (blarcamesine) in Parkinson’s Disease Dementia Oct 16
New 90-day high: €5.00 Oct 16
New 90-day low - €3.18 Sep 09
Anavex Life Sciences Corp. to Report Q3, 2020 Results on Aug 06, 2020 Aug 06 Shareholder Returns 12X1 DE Biotechs DE Market 7D 2.3% 1.1% -0.2% 1Y -3.0% -14.5% 7.0%
See full shareholder returns
Return vs Market: 12X1 underperformed the German Market which returned 7% over the past year.
Price Volatility Is 12X1's price volatile compared to industry and market? 12X1 volatility 12X1 Average Weekly Movement 14.0% Biotechs Industry Average Movement 7.0% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.7% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 12X1's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 12X1's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases in the United States. The company’s lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer’s disease and Parkinson’s disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. It also provides ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer’s disease.
Show more Anavex Life Sciences Corp. Fundamentals Summary How do Anavex Life Sciences's earnings and revenue compare to its market cap? 12X1 fundamental statistics Market cap €1.02b Earnings (TTM ) -€41.26m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 12X1 income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$43.00m Earnings -US$43.00m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/27 19:52 End of Day Share Price 2024/12/23 00:00 Earnings 2024/09/30 Annual Earnings 2024/09/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Anavex Life Sciences Corp. is covered by 14 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Caroline Palomeque Berenberg Yun Zhong BTIG Charles Duncan Cantor Fitzgerald & Co.
Show 11 more analysts 
